Uploaded April 2022 | Updated September 2026, 1 day ago

---

A new cohort of obesity drugs, called GLP1 receptor agonists, are so effective and safe that they will likely be put into widespread use for the treatment of obesity and achieve unparalleled success in the treatment of this disease—on par with bariatric surgery, but without the surgery. In this video I discuss the latest science and the promise of these drugs—as well as two other new classes of drugs that show similar (and synergistic) promise.

Links to references, in the order that they were discussed:
STEP1, semaglutide:
nejm.org/doi/10.1056/NEJMoa2032183

STEP4, semaglutide:
jamanetwork.com/journals/jama/fullarticle/2777886

Semaglutide plus cagrilintide:
thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/fulltext

Meta-analysis of long-term outcomes:
clinicalkey.com/#!/content/playContent/1-s2.0-S2213858719302499

Tirzepatide clinical trial registration:
clinicaltrials.gov/ct2/show/NCT04184622

Bimagrumab:
jamanetwork.com/journals/jamanetworkopen/fullarticle/2774903

Small molecule GLP1 receptor agonist:
diabetesjournals.org/diabetes/article/69/Supplement_1/353-OR/56321/353-OR-Oral-Small-Molecule-GLP-1R-Agonist-PF

===

Like, comment, subscribe.

For more, find me at:
PODCAST The Kevin Bass Show
YOUTUBE youtube.com/user/kbassphiladelphia
WEBSITE thedietwars.com
TWITTER twitter.com/kevinnbass
twitter.com/healthmisinfo
INSTAGRAM instagram.com/kevinnbass
TIKTOK tiktok.com/@kevinnbass

And above all, please donate to support what I do:
PATREON patreon.com/kevinnbass
DONATE thedietwars.com/support-me